Omalizumab Therapeutic Cheat Sheet
OmalizumabChronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …
Omalizumab
Dutasteride Therapeutic Cheat Sheet
Androgenic alopecia (AGA) is one of the most common forms of hair loss and represents a frequently faced disabling concern in dermatology visits. Targeting the 5α-dihydrotestosterone (DHT) pathway has been shown to be an efficacious mechanism of action, with finasteride being the only systemic FDA-approved drug to treat male AGA. Recently, its sister drug, dutasteride, has been increasingly utili …
Efinaconazole for Toenail Onychomycosis | Therapeutic Cheat Sheet
EfinaconazoleOnychomycosis is an extremely common and difficult to treat condition. We have numerous oral and topical treatments in our therapeutic repertoire, but oral medication use is often limited by the risk of hepatotoxicity or drug interactions. Traditional topical lacquers, on the other hand, have limited efficacy due to their inability to adequately penetrate the nail plate. Efinaconazole is a newer t …
Efinaconazole
Tralokinumab-ldrm Therapeutic Cheat Sheet
tralokinumabAtopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
tralokinumab
Clascoterone Cream | Therapeutic Cheat Sheet
clascoteroneClascoterone cream is a novel topical therapeutic agent used to treat acne vulgaris through androgen inhibition. Other androgen inhibitors such as combined oral contraceptive pills and off-label spironolactone can lead to some unwanted side effects such as feminization, gynecomastia, and erectile dysfunction, making them unsuitable for male patients. Unlike other androgen inhibitors used to manage …
clascoterone